4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD

• 4D Molecular Therapeutics reported positive 2-year Phase 2b PRISM data for wet AMD gene therapy 4D-150, supporting its Phase 3 program.
• Single intravitreal dose maintained visual acuity and retinal anatomy through 2 years, with durable reduction in supplemental anti-VEGF injections.
• Overall cohort showed 78% treatment-burden reduction; recently diagnosed subgroup showed 87% reduction versus 12 projected aflibercept injections over 2 years.
• Safety profile stayed stable; 2.8% mild intraocular inflammation within 28 weeks, no new inflammation reported beyond 28 weeks with up to 4+ years follow-up.
• 3E10 vg/eye selected as the Phase 3 dose; trial enrolled 45 patients across two dose levels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607181515PRIMZONEFULLFEED9763531) on July 18, 2026, and is solely responsible for the information contained therein.